FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer.

IF 2.3 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Chenxu Meng, Yang Yang, Pengfei Ren, Qian Ju, Xiangting Jin, Qihe Long, Xiangyu Chen, Xian Wang, Fanfan Li
{"title":"FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer.","authors":"Chenxu Meng,&nbsp;Yang Yang,&nbsp;Pengfei Ren,&nbsp;Qian Ju,&nbsp;Xiangting Jin,&nbsp;Qihe Long,&nbsp;Xiangyu Chen,&nbsp;Xian Wang,&nbsp;Fanfan Li","doi":"10.1177/03936155221110249","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Fidgetin-like 1</i> <i>(FIGNL1</i>) participates in tumor resistance by playing the function of homologous recombination repair(HRR). However, the role of <i>FIGNL1</i> in non-small cell lung cancer (NSCLC) is still unclear. This study aims to understand the expression of <i>FIGNL1</i> in NSCLC and preliminarily explore its relationship with cisplatin resistance.</p><p><strong>Methods: </strong><i>FIGNL1</i> messenger RNA (mRNA) was analyzed in 1018 NSCLC tissues and 111 adjacent tissues using The Cancer Genome Atlas program. <i>FIGNL1</i>mRNA in cisplatin-resistant and cisplatin-sensitive cell lines was analyzed by the Gene Expression Omnibus project. FIGNL1 protein was detected in 58 NSCLC tissues and 58 adjacent tissues by immunohistochemistry. The relationship between FIGNL1, clinical pathological characteristics and disease-free survival was retrospectively analyzed. Gene ontology was used to analyze the biological process mainly involving <i>FIGNL1</i>, and STRING online constructed its protein interaction network and screened the key genes (hub genes).</p><p><strong>Results: </strong>The Cancer Genome Atlas showed that <i>FIGNL1</i>mRNA was higher in 1018 NSCLC tissues than in 111 adjacent tissues (<i>P</i> < 0.05). In the dataset \"GSE157692,\" <i>FIGNL1</i>mRNA was higher in cisplatin-resistant cell lines (<i>P</i> = 3.80e-05). The hub genes in <i>FIGNL1</i> and HRR directions are <i>RAD51</i> and <i>CCDC36</i>. Immunohistochemistry showed that the FIGNL1 protein in 58 NSCLC tissues was higher than that in 58 adjacent tissues (<i>P</i> < 0.01). FIGNL1 is associated with gender, histopathological type, and nerve invasion in NSCLC. The disease-free survival in NSCLC patients with high FIGNL1 expression was shorter (<i>P</i> = 0.032).</p><p><strong>Conclusion: </strong>FIGNL1 is associated with poor prognosis in NSCLC, and cisplatin resistance may be involved. These observations provide a clinical basis for exploring FIGNL1 as a potential biomarker for cisplatin resistance in NSCLC.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155221110249","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Fidgetin-like 1 (FIGNL1) participates in tumor resistance by playing the function of homologous recombination repair(HRR). However, the role of FIGNL1 in non-small cell lung cancer (NSCLC) is still unclear. This study aims to understand the expression of FIGNL1 in NSCLC and preliminarily explore its relationship with cisplatin resistance.

Methods: FIGNL1 messenger RNA (mRNA) was analyzed in 1018 NSCLC tissues and 111 adjacent tissues using The Cancer Genome Atlas program. FIGNL1mRNA in cisplatin-resistant and cisplatin-sensitive cell lines was analyzed by the Gene Expression Omnibus project. FIGNL1 protein was detected in 58 NSCLC tissues and 58 adjacent tissues by immunohistochemistry. The relationship between FIGNL1, clinical pathological characteristics and disease-free survival was retrospectively analyzed. Gene ontology was used to analyze the biological process mainly involving FIGNL1, and STRING online constructed its protein interaction network and screened the key genes (hub genes).

Results: The Cancer Genome Atlas showed that FIGNL1mRNA was higher in 1018 NSCLC tissues than in 111 adjacent tissues (P < 0.05). In the dataset "GSE157692," FIGNL1mRNA was higher in cisplatin-resistant cell lines (P = 3.80e-05). The hub genes in FIGNL1 and HRR directions are RAD51 and CCDC36. Immunohistochemistry showed that the FIGNL1 protein in 58 NSCLC tissues was higher than that in 58 adjacent tissues (P < 0.01). FIGNL1 is associated with gender, histopathological type, and nerve invasion in NSCLC. The disease-free survival in NSCLC patients with high FIGNL1 expression was shorter (P = 0.032).

Conclusion: FIGNL1 is associated with poor prognosis in NSCLC, and cisplatin resistance may be involved. These observations provide a clinical basis for exploring FIGNL1 as a potential biomarker for cisplatin resistance in NSCLC.

FIGNL1是非小细胞肺癌顺铂耐药的潜在生物标志物。
背景:Fidgetin-like 1 (FIGNL1)通过发挥同源重组修复(homologous recombination repair, HRR)功能参与肿瘤抵抗。然而,FIGNL1在非小细胞肺癌(NSCLC)中的作用尚不清楚。本研究旨在了解FIGNL1在NSCLC中的表达,并初步探讨其与顺铂耐药的关系。方法:使用Cancer Genome Atlas程序对1018例NSCLC组织和111例癌旁组织中FIGNL1信使RNA (mRNA)进行分析。通过基因表达综合项目分析顺铂耐药和顺铂敏感细胞株中FIGNL1mRNA的表达。免疫组化检测58例NSCLC组织及58例癌旁组织中FIGNL1蛋白。回顾性分析FIGNL1与临床病理特征及无病生存的关系。利用基因本体分析主要涉及FIGNL1的生物学过程,STRING在线构建其蛋白相互作用网络,筛选关键基因(枢纽基因)。结果:肿瘤基因组图谱显示,1018例NSCLC组织中FIGNL1mRNA表达高于111例癌旁组织(P < 0.05)。在数据集“GSE157692”中,FIGNL1mRNA在顺铂耐药细胞系中较高(P = 3.80e-05)。FIGNL1和HRR方向的枢纽基因为RAD51和CCDC36。免疫组化结果显示58例NSCLC组织中FIGNL1蛋白表达高于58例相邻组织(P P = 0.032)。结论:FIGNL1与NSCLC预后不良相关,可能与顺铂耐药有关。这些观察结果为探索FIGNL1作为非小细胞肺癌顺铂耐药的潜在生物标志物提供了临床基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Biological Markers
International Journal of Biological Markers 医学-生物工程与应用微生物
CiteScore
4.10
自引率
0.00%
发文量
43
期刊介绍: IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信